Century Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Century Therapeutics, Inc. (IPSC) reported Capital Expenditures Incurred but Not yet Paid of $352.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-05-09
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was $298.00K, a 78.95% decline year-over-year.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was -$1.58M, a 271.35% decline year-over-year.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $664.00K.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $975.00K, a 74.32% decline year-over-year.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $352.00K, a 86.74% decline from fiscal 2022.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $2.65M, a 95.15% increase from fiscal 2021.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $1.36M, a 69.59% decline from fiscal 2020.
- Century Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $4.47M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2023-12-31 | $298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$1.29M derived: sum of 2 quarters · filed 2024-03-14 | -$623.00K derived: sum of 3 quarters · filed 2024-03-14 | $352.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$921.00K derived: sum of 2 quarters · filed 2023-11-09 | $54.00K 10-Q · filed 2023-11-09 | $1.47M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.64M 10-Q · filed 2023-08-09 | $3.06M derived: sum of 3 quarters · filed 2024-05-09 | $3.98M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $975.00K 10-Q · filed 2024-05-09 | $2.39M derived: sum of 2 quarters · filed 2024-05-09 | $3.32M derived: sum of 3 quarters · filed 2024-05-09 | -$167.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.34M derived: sum of 2 quarters · filed 2024-03-14 | -$1.14M derived: sum of 3 quarters · filed 2024-03-14 | $2.65M 10-K · filed 2024-03-14 |
| 2022-09-30 | $925.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.56M derived: sum of 2 quarters · filed 2023-11-09 | $1.24M 10-Q · filed 2023-11-09 | -$5.10M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$3.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $313.00K 10-Q · filed 2023-08-09 | -$6.03M derived: sum of 3 quarters · filed 2023-08-09 | -$6.54M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $3.80M 10-Q · filed 2023-05-11 | -$2.54M derived: sum of 2 quarters · filed 2023-05-11 | -$3.06M derived: sum of 3 quarters · filed 2023-05-11 | $3.59M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$6.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$6.85M derived: sum of 2 quarters · filed 2023-03-16 | -$205.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.36M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$514.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $6.13M derived: sum of 2 quarters · filed 2022-11-10 | $7.70M 10-Q · filed 2022-11-10 | $11.09M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $6.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $8.21M 10-Q · filed 2022-08-11 | $11.60M derived: sum of 3 quarters · filed 2022-08-11 | $12.54M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.56M 10-Q · filed 2022-05-16 | $4.95M derived: sum of 2 quarters · filed 2022-05-16 | $5.89M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $4.32M derived: sum of 2 quarters · filed 2022-03-17 | $4.47M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $936.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.09M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $150.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |